---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-051566"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T00:48:53.931527+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kymera Therapeutics Q1 2024 net loss $48.6M; cash $745M; pipeline progresses

## Summary
- Net loss $48.6M in Q1 2024 vs $40.9M in Q1 2023; collaboration revenue $10.3M.
- Cash, cash equivalents and investments $745M as of March 31, 2024.
- Cash runway extended into first half of 2027 following $301M equity offering.
- KT-474 IRAK4 degrader Phase 2 trials in HS and AD ongoing; topline data H1 2025.
- KT-621 STAT6 degrader Phase 1 start H2 2024; KT-294 TYK2 degrader Phase 1 start H1 2025.

## SEC filing metadata
- accession: 0000950170-24-051566
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000095017024051566/0000950170-24-051566-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000095017024051566/kymr-20240502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-051566
- JSON: https://secwatch.observer/filing/0000950170-24-051566.json
- Plain text: https://secwatch.observer/filing/0000950170-24-051566.txt

## Key facts
- Earnings Releases
  Kymera Therapeutics, Inc. reported financial results for the quarter ended March 31, 2024.
  - Period: the quarter ended March 31, 2024
  - Result: reported results
  source text: On May 2, 2024, Kymera Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815442/000095017024051566/0000950170-24-051566-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.